BridgeMD
Tests treatment safety and results for Migraine Disorders
Official title Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks
ClinicalTrials.gov ID: NCT07093138
What this study is testing
What is Canvert-M (Produced by Alasht Pharmed co. Iran)?
Canvert-M (Produced by Alasht Pharmed co. Iran) is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for migraine disorders.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Canvert-M (manufactured by Alasht Pharmed Co. Iran) is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 55
You may be able to join if
- Males and females with age of 18 to 55 years
- Age of migraine onset ˂ 50 years
- Having a diagnosis of migraine according to the International Classification of Headache Disorders 3rd edition (ICHD-3) for at least one year
- Having a history of 2-8 attacks per month
- Remaining stable on prophylactic medication (if used) during the 2 months prior to screening and throughout the study period
You likely can't join if
- Having a diagnosis of other primary (cluster and tension) and secondary headache disorders
- Having a history of chronic migraine headache
- History of resistant or refractory migraine headaches based on European Headache Federation consensus
- Receiving any abortive medication for the treatment of migraine within 48 hours before using Canvert-M
- History of psychiatric and neurologic disorders (except migraine) or any medical comorbid conditions that interfere with the study results
- History of nasal sensitivity or allergy to menthol, lavender, rosemary, eucalyptus, wintergreen and basil oil
See the full eligibility criteria
- Males and females with age of 18 to 55 years
- Age of migraine onset ˂ 50 years
- Having a diagnosis of migraine according to the International Classification of Headache Disorders 3rd edition (ICHD-3) for at least one year
- Having a history of 2-8 attacks per month
- Remaining stable on prophylactic medication (if used) during the 2 months prior to screening and throughout the study period
- Using effective contraception by the women of childbearing potential during the study
- Ability to provide written, informed consent and to be compliant with the schedule of protocol assessments
- Having a diagnosis of other primary (cluster and tension) and secondary headache disorders
- Having a history of chronic migraine headache
- History of resistant or refractory migraine headaches based on European Headache Federation consensus
- Receiving any abortive medication for the treatment of migraine within 48 hours before using Canvert-M
- History of psychiatric and neurologic disorders (except migraine) or any medical comorbid conditions that interfere with the study results
- History of nasal sensitivity or allergy to menthol, lavender, rosemary, eucalyptus, wintergreen and basil oil
- The presence of any skin lesions in the areas where the product is used
- Treatment with any investigational agent within 30 days prior to screening
- History of substance use disorders
- Nursing mothers, pregnant women, and women who plan to become pregnant during the study period
- Taking carbamazepine, cilostazol, citalopram, clarithromycin, clobazam, colchicine, cyclosporine, digoxin, itraconazole, phenobarbital, phenytoin, rifampin, sirolimus, tacrolimus, tizanidine, and warfarin within 14 days...
The study team makes the final eligibility decision.
Where it's taking place
- Tehran, Iran
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 55 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tehran, Iran. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.